Abstracts tagged "prednisone and pregnancy"

Abstract Number: 930 • 2017 ACR/ARHP Annual Meeting
Efficacy and Safety of Modified-Release Prednisone in Managing Moderate Activity SLE during Pregnancy: An Implemented Case-Control Study
Marianna Meroni¹, Véronique Laure Ramoni², Massimiliano Parodi³, Paolo Stobbione³ and Maurizio Cutolo⁴, ¹Research Laboratory and Academic Division of Clinical Rheumatology, Department of Internal Medicine, IRCCS A.O.U. San Martino-IST, University of Genova, Genoa, Italy, Genova, Italy, ²Division of Rheumatology, IRCCS San Matteo Hospital Foundation, University of Pavia, Pavia, Italy, Pavia, Italy, ³Rheumatology Unit, Internal Medicine Department, A.O. S.S. Antonio e Biagio e Cesare Arrigo, Alessandria, Italy, Alessandria, Italy, ⁴Research Laboratory and Academic Division of Clinical Rheumatology, Department of Internal Medicine, IRCCS A.O.U. San Martino-IST, University of Genova, Genoa, Italy, Genoa, Italy
Background/Purpose: Systemic lupus erythematosus (SLE) can affect young women and pregnancy still represents a challenge. Prednisone is safely used, at low doses (<7.5 mg daily),…
Abstract Number: 1224 • 2012 ACR/ARHP Annual Meeting
Rheumatoid Arthritis Disease Activity During Pregnancy Affects the Postnatal Catch-up Growth of the Child
Florentien D.O. de Steenwinkel¹, Anita C.S. Hokken-Koelega², Maria A.J. de Ridder³, Johanna M.W. Hazes⁴ and Radboud J.E.M. Dolhain¹, ¹Rheumatology, Erasmus Medical Center, Rotterdam, Netherlands, ²Pediatrics, Subdivision of Endocrinology, Erasmus Medical Center- Sophia Children's Hospital, Rotterdam, Netherlands, ³Bio Statistics, Erasmus Medical Center, Rotterdam, Netherlands, ⁴Rheumatology, Erasmus MC, Rotterdam, Netherlands
Background/Purpose: Active rheumatoid arthritis (RA) during pregnancy is associated with lower birth weight. Active RA during pregnancy can be treated with prednisone. However, studies have…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].